Physician profile
Steven Galen
NPI 1396702320
$11,538.50
in general payments reported to CMS, 2019-2025
55 companies · $1,918 in 2025
The $1,918 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,370 · 2020: $1,185 · 2021: $1,174 · 2022: $1,259 · 2023: $843 · 2024: $1,788 · 2025: $1,918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,531 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,531.35 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,785.14 | 2019-2025 | |
| Amgen INC. | $1,126.04 | 2019-2025 | Repatha, Otezla, Tepezza |
| Dexcom, INC. | $980.51 | 2019-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $794.02 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $661.93 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $627.56 | 2019-2025 | Breztri, Fasenra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $524.01 | 2019-2024 | Xifaxan |
| Pfizer INC. | $473.96 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $397.90 | 2019-2025 | |
| Allergan, INC. | $384.30 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $357.34 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $346.33 | 2019-2022 | |
| Insulet Corporation | $274.76 | 2019-2024 | Omnipod |
| Takeda Pharmaceuticals U.S.A., INC. | $270.76 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $255.86 | 2019-2022 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Galen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.